1989 related articles for article (PubMed ID: 19162288)
21. Antibody effector mechanisms in myasthenia gravis-pathogenesis at the neuromuscular junction.
Gomez AM; Van Den Broeck J; Vrolix K; Janssen SP; Lemmens MA; Van Der Esch E; Duimel H; Frederik P; Molenaar PC; Martínez-Martínez P; De Baets MH; Losen M
Autoimmunity; 2010 Aug; 43(5-6):353-70. PubMed ID: 20380584
[TBL] [Abstract][Full Text] [Related]
22. Association of neonatal myasthenia gravis with antibodies against the fetal acetylcholine receptor.
Vernet-der Garabedian B; Lacokova M; Eymard B; Morel E; Faltin M; Zajac J; Sadovsky O; Dommergues M; Tripon P; Bach JF
J Clin Invest; 1994 Aug; 94(2):555-9. PubMed ID: 8040310
[TBL] [Abstract][Full Text] [Related]
23. Myasthenia gravis and myasthenic syndromes.
Engel AG
Ann Neurol; 1984 Nov; 16(5):519-34. PubMed ID: 6095730
[TBL] [Abstract][Full Text] [Related]
24. [Clinical correlation of anti-receptor antibody titer, sensitivity to curare and electromyographic changes in experimental autoimmune myasthenia gravis].
Chen SM
Zhonghua Shen Jing Jing Shen Ke Za Zhi; 1990 Oct; 23(5):293-6, 320. PubMed ID: 2282884
[TBL] [Abstract][Full Text] [Related]
25. Thymus histology and concomitant autoimmune diseases in Japanese patients with muscle-specific receptor tyrosine kinase-antibody-positive myasthenia gravis.
Nakata R; Motomura M; Masuda T; Shiraishi H; Tokuda M; Fukuda T; Ando T; Yoshimura T; Tsujihata M; Kawakami A
Eur J Neurol; 2013 Sep; 20(9):1272-6. PubMed ID: 23679930
[TBL] [Abstract][Full Text] [Related]
26. Myasthenia gravis experimentally induced with muscle-specific kinase.
Shigemoto K; Kubo S; Jie C; Hato N; Abe Y; Ueda N; Kobayashi N; Kameda K; Mominoki K; Miyazawa A; Ishigami A; Matsuda S; Maruyama N
Ann N Y Acad Sci; 2008; 1132():93-8. PubMed ID: 18096854
[TBL] [Abstract][Full Text] [Related]
27. [Value of acetylcholine receptor antibodies in myasthenia gravis].
Zeitlhofer J; Maida EM; Mamoli B; Mayr N
Wien Med Wochenschr; 1986 Jul; 136(13):329-32. PubMed ID: 3765651
[TBL] [Abstract][Full Text] [Related]
28. Myasthenia gravis patients with anti-MuSK antibodies.
Zagar M; Vranjes D; Sostarko M; Vogrinc Z; Bilić E; Trbojević Cepe M
Coll Antropol; 2009 Dec; 33(4):1151-4. PubMed ID: 20102061
[TBL] [Abstract][Full Text] [Related]
29. Refractoriness to a second episode of experimental myasthenia gravis. Correlation with AChR concentration and morphologic appearance of the postsynaptic membrane.
Corey AL; Richman DP; Agius MA; Wollmann RL
J Immunol; 1987 May; 138(10):3269-75. PubMed ID: 3494763
[TBL] [Abstract][Full Text] [Related]
30. Acetylcholine receptor antibodies in myasthenia gravis.
Kornfeld P; Nall J; Smith H; Mittag TW; Bender AN; Ambinder EP; Horowitz SH; Papatestas AE; Gross H; Genkins G
Muscle Nerve; 1981; 4(5):413-9. PubMed ID: 6974823
[TBL] [Abstract][Full Text] [Related]
31. Teratogen update: maternal myasthenia gravis as a cause of congenital arthrogryposis.
Polizzi A; Huson SM; Vincent A
Teratology; 2000 Nov; 62(5):332-41. PubMed ID: 11029151
[TBL] [Abstract][Full Text] [Related]
32. Use of Torpedo-mouse hybrid acetylcholine receptors reveals immunodominance of the alpha subunit in myasthenia gravis antisera.
Loutrari H; Tzartos SJ; Claudio T
Eur J Immunol; 1992 Nov; 22(11):2949-56. PubMed ID: 1385157
[TBL] [Abstract][Full Text] [Related]
33. Acetylcholine receptors loss and postsynaptic damage in MuSK antibody-positive myasthenia gravis.
Shiraishi H; Motomura M; Yoshimura T; Fukudome T; Fukuda T; Nakao Y; Tsujihata M; Vincent A; Eguchi K
Ann Neurol; 2005 Feb; 57(2):289-93. PubMed ID: 15668981
[TBL] [Abstract][Full Text] [Related]
34. The thymus in myasthenia gravis. Changes typical for the human disease are absent in experimental autoimmune myasthenia gravis of the Lewis rat.
Meinl E; Klinkert WE; Wekerle H
Am J Pathol; 1991 Nov; 139(5):995-1008. PubMed ID: 1951638
[TBL] [Abstract][Full Text] [Related]
35. Prevention of experimental autoimmune myasthenia gravis by a monoclonal antibody to a complementary peptide for the main immunogenic region of the acetylcholine receptors.
Araga S; Galin FS; Kishimoto M; Adachi A; Blalock JB
J Immunol; 1996 Jul; 157(1):386-92. PubMed ID: 8683141
[TBL] [Abstract][Full Text] [Related]
36. Passive and active immunization models of MuSK-Ab positive myasthenia: electrophysiological evidence for pre and postsynaptic defects.
Viegas S; Jacobson L; Waters P; Cossins J; Jacob S; Leite MI; Webster R; Vincent A
Exp Neurol; 2012 Apr; 234(2):506-12. PubMed ID: 22326541
[TBL] [Abstract][Full Text] [Related]
37. Passive transfer of experimental myasthenia gravis via antigenic modulation of acetylcholine receptor.
Loutrari H; Kokla A; Tzartos SJ
Eur J Immunol; 1992 Sep; 22(9):2449-52. PubMed ID: 1516631
[TBL] [Abstract][Full Text] [Related]
38. Anti-AChR-negative myasthenia gravis: clinical and immunological features.
Evoli A; Bartoccioni E; Batocchi AP; Scuderi F; Tonali P
Clin Invest Med; 1989 Apr; 12(2):104-9. PubMed ID: 2706833
[TBL] [Abstract][Full Text] [Related]
39. Clinical comparison of anti-MuSK- vs anti-AChR-positive and seronegative myasthenia gravis.
Deymeer F; Gungor-Tuncer O; Yilmaz V; Parman Y; Serdaroglu P; Ozdemir C; Vincent A; Saruhan-Direskeneli G
Neurology; 2007 Feb; 68(8):609-11. PubMed ID: 17310034
[TBL] [Abstract][Full Text] [Related]
40. Molecular aspects of experimental autoimmune myasthenia gravis.
Fuchs S; Bartfeld D; Mochly-Rosen D; Schmidt-Hopfeld I; Tarrab-Hazdai R
Prog Clin Biol Res; 1981; 63():405-17. PubMed ID: 7031685
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
